For the first time in around eleven months, the corona incidence fell below 5.

The Robert Koch Institute (RKI) gave the nationwide value on Saturday morning as 4.9.

The day before it was 5.0, the week before it was 5.9.

Most recently, on July 30, 2020, the value was 4.8 below the 5 threshold.

The health authorities in Germany also reported 671 new corona infections within one day, as can be seen from the numbers from the morning, which reflect the status of the RKI dashboard from 5:01 a.m.

For comparison: a week ago 592 infections were registered.

According to this information, 16 deaths were recorded across Germany within 24 hours.

A week ago there were 68 dead.

The RKI has counted 3,730,353 detected infections with Sars-CoV-2 since the beginning of the pandemic.

The actual total number is likely to be significantly higher, as many infections are not detected.

The RKI stated the number of those who had recovered at around 3,627,800.

The number of people who died with or with a proven infection with Sars-CoV-2 rose to 91,023.

General practitioners criticize Stiko's AstraZeneca communication

Germany’s GPs meanwhile complain that the new recommendation of the Standing Vaccination Commission (Stiko) for cross-vaccination with AstraZeneca presents them with enormous challenges. "Patients are insecure, ask which vaccine they will now receive with the second vaccination and want to bring their appointment forward accordingly. For them, of course - especially with a view to the upcoming summer holidays - it makes a big difference whether they wait nine to twelve weeks for their second vaccination or just four, "said the federal chairman of the German Association of General Practitioners, Ulrich Weigeldt, the editorial network Germany. The adjustment of the recommendation caused "enormous additional effort" in many practices on the first day.

The vaccination commission surprisingly announced on Thursday that people who had received a first dose of the corona vaccine from Astrazeneca should in future receive an mRNA vaccine like the one from Biontech or Moderna as a second syringe, regardless of age.

Of course, it is the task of science to adapt recommendations to the current state of knowledge, said Weigeldt.

“But that does not speak against clear communication and the early involvement of those who ultimately implement the recommendations.

If we falter, so does the entire vaccination campaign. "